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Nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, are common neoplasms worldwide and
are the most common cancers in the United States. Standard therapy for cutaneous neoplasms typically involves surgical removal.
However, there is increasing interest in the use of topical alternatives for the prevention and treatment of nonmelanoma skin
cancer, particularly superficial variants. Botanicals are compounds derived from herbs, spices, stems, roots, and other substances
of plant origin and may be used in the form of dried or fresh plants, extracted plant material, or specific plant-derived chemicals.
They possess multiple properties including antioxidant, anti-inflammatory, and immunomodulatory properties and are, therefore,
believed to be possible chemopreventive agents or substances that may suppress or reverse the process of carcinogenesis. Here, we
provide a review of botanical agents studied for the treatment and prevention of nonmelanoma skin cancers.
1. Introduction
Nonmelanoma skin cancer (NMSC) is common worldwide
and includes basal cell carcinoma (BCC) and squamous
cell carcinoma (SCC). Approximately two to three million
NMSCs occur globally each year [1]. In the United States
(U.S.), BCC is the most common form of malignancy [2, 3].
In 2012, two million new cases of NMSCs were estimated
to occur in the U.S., with delays in treatment leading
to significant morbidity [4] and deaths occurring in less
than 1,000 [5]. Delay in treatment of NMSCs can lead to
significant morbidity as well. Extrinsic and intrinsic risk
factors contribute to skin cancer development including
fair skin color, red and blond hair, and high susceptibility
to sunburn [6]. Chronic sun exposure is also associated
with skin cancer risk, especially for SCC [7]. Furthermore,
chronically immunocompromised organ transplant patients
have a higher risk of developing SCCs [8, 9].
Traditional recommendations for prevention of NMSC
include generous use of sunscreens and avoidance of chronic
or intense ultraviolet (UV) exposure. Conventional therapy
forNMSCs involves surgical removal or directed topical ther-
apies in the most superficial subtypes of NMSC. However,
there is increasing interest in alternative, noninvasive treat-
ments and preventative measures in recent years, specifically
in the use of naturally occurring botanicals. Botanicals are
a group of compounds derived from herbs, spices, stems,
roots, and other substances of plant origin and may be used
in the form of dried or fresh plants or extracted plantmaterial
[10]. They possess multiple properties including antioxidant,
anti-inflammatory, and immunomodulatory properties, and,
therefore, they are believed to be possible chemopreventive
agents or substances that may suppress or reverse the process
of carcinogenesis [7]. For example, topical ingenol mebutate,
extracted from Euphorbia, was recently approved by the
U.S. Food and Drug Administration (FDA) for treatment of
actinic keratosis [11]. There is perceived safety and efficacy
with botanicals despite a lack of controlled clinical trials and
scientific data [10]. Furthermore, botanical extracts are often
distributed as dietary supplements in the United States with
little regulation [12]. Therefore, there is need for controlled
studies that evaluate both of their efficacy and side effects.
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Here, we review botanical agents that have been used for
the treatment and prevention of NMSCs. Botanical agents
studied in humans as well as agents investigated in preclinical
trials are reviewed.
2. Methods
We conducted a search of the PubMed and Embase databases
of articles published from 1990 to 2013 to include the
most recent literature. Articles containing combinations of
MeSH terms “nonmelanoma skin cancer,” “basal cell carci-
noma,” “squamous cell carcinoma,” “complementary thera-
pies,” “plant preparations,” “edible plants,” “herbal medicine,”
“antineoplastic agents,” “phytogenic,” and “botanical” were
reviewed. Based on the initial review using these terms,
botanical agents and extracts identified as having possible
effects on NMSC treatment and prevention through studies,
reviews, and case reports, were reviewed. The search was
limited to articles in English and initially resulted in 91
articles. The article abstracts were reviewed for relevance to
the subject matter of treatment and prevention of UV light-
induced NMSCs, BCCs, and SCCs, using botanical agents.
We examined reference lists to identify any missing articles,
and a total of 74 articles were included in this review. We
included only botanical agents that have been investigated in
more than one study and/or have been reported inmore than
one case.
3. Botanical Agents Studied in Humans and
Animals (Tables 1 and 2)
3.1. Ingenol Mebutate. Ingenol mebutate is an extract from
the Euphorbia peplus (E. peplus) plant that has been identi-
fied for its chemotherapeutic potential, and, more recently,
approved by the U.S. FDA for the treatment of actinic
keratoses. Preclinical studies in murine models have shown
that ingenol mebutate causes mitochondrial swelling of the
dysplastic keratinocytes and apoptosis by primary necrosis
[48]. In a phase I/II clinical study to determine the efficacy
of the E. peplus sap, for which the main ingredient was
ingenol mebutate, on the treatment of BCCs, SCCs, and
intraepidermal carcinomas, Ramsay et al. enrolled 36 patients
with a total of 48 lesions who had failed past treatments,
refused surgical treatment, or were found unfit for surgical
therapy due to anticoagulant use, age, site, or nature of
the lesion [13]. Patients were treated once daily for three
consecutive days. Complete clinical response (tumor absence
after clinical examination) following treatment was 82% (𝑛 =
28) for BCCs, 75% (𝑛 = 4) for SCCs, and 94% (𝑛 = 16) for
intraepidermal carcinomas at 1 month [13]. However, partial
responses were noted in five of the BCCs treated. Although
the authors note that 6 of the treated BCCs were of the
nodular subtypewhile the rest were of the superficial subtype,
they do not mention if it was the nodular subtypes that were
the partially responding tumors. Also, a full histopathological
examination of the treatment sites was not performed as the
subjects were not suitable surgical candidates. Instead, 2–4
millimeter (mm) biopsy samplingswere obtained but thiswas
only partial sampling as the average size of the NMSC was
noted to be 16mm. The most common side effects included
dry skin, erythema, and patchy moist desquamation. After
a mean of 15 months for followup, the complete clinical
response rates were 57% for BCCs, 50% for SCCs, and 75% for
intraepidermal carcinomas [13]. For superficial carcinomas
that were less than 16mm, the complete clinical response
rates were 78% (𝑛 = 9) for BCCs and 100% (𝑛 = 10) for
intraepidermal carcinomas [13].
Furthermore, a phase IIa randomized, vehicle-controlled
study of 60 patients evaluated the safety (primary endpoint)
and efficacy (secondary endpoint) of ingenol mebutate gel
for superficial basal cell carcinoma, with a lesion size of 4–
15mm. In this study, Siller et al. randomized patients to Arm
A, treatment on days 1 and 2, or Arm B, treatment on days 1
and 8 [14]. Within each arm, patients were also randomized
to application of ingenol mebutate gel 0.0025%, 0.01%, or
0.05%, or amatching vehicle gel [14].No severe adverse events
were reported. In four patients, severe local skin reactions
occurred.Themost common side effects were erythema, flak-
ing, scaling, and dryness.Thehistopathological clearance rate
was 71% (5/7) in the treatment group of Arm A that received
0.05% ingenolmebutate gel, and 86% (6/7) showedmarked or
complete clearance (50–90%) on clinical examination [14].
3.2. Hypericin. Hypericum perforatum, St. John’s wort, con-
tains the photoactive compound, hypericin, which is a potent
photosensitizer in photodynamic therapy. It is activated
by visible (400–700 nm) or UVA (320–400 nm) light [49].
Hypericin has demonstrated cytotoxic and antiproliferative
properties against cancer cells. Although an early study by
Alecu et al. reported that hypericinwas effective for treatment
of BCCs and SCCs without necrosis of the surrounding tissue
when injecting hypericin solution intralesionally and then
irradiating the site with visible light [15], subsequent studies
did not demonstrate efficacy of hypericin in skin cancer
treatment.
A prospective pilot study by Kacerovska´ et al. investigated
the use of an extract of H. perforatum in combination
with photodynamic therapy for BCCs, actinic keratoses,
and Bowens disease (carcinoma in situ) [16]. A total of 34
patients were enrolled, 21 of which had BCCs. The extract
was applied under occlusion to the skin lesions, followed
two hours later by irradiation with 75 Joules per square
centimeter (J/cm2) of red light. Patients underwent treatment
for six weeks on average. They found complete clinical
response for 28% of superficial BCC patients, and only
partial remission was seen in nodular BCC patients [16].
By histology, a complete disappearance of cancer cells was
found in 11% of the superficial BCCs [16]. All patients in the
study complained of pain and burning during irradiation.
The authors concluded that the results of this clinical trial
showed that this combination therapy was not effective and
that further studies are needed to examine the enhancement
of hypericin delivery. Furthermore, a recent study by Boiy
et al. demonstrated that topical hypericin with photodynamic
therapy was less effective in clearance of UV light-induced
tumors in mouse skin as compared to methylaminolevulinic
acid with photodynamic therapy (44% clearance of skin
tumors as compared to 80% clearance, resp.) [30].
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Table 1: Summary of the effects of botanical agents studied in humans.
Botanical
agent Source Efficacy
Histopathological
assessment of
efficacy
References
Ingenol
mebutate Euphorbia peplus
Demonstrated clinical response (tumor clearance) for
BCCs and SCCs. No [13, 14]
Hypericin Hypericum perforatum
Reported clinical response for BCCs and SCCs to
hypericin and photodynamic therapy in one study
[15], but found the combination to be less effective in
another human study [16].
Yes [15, 16]
Coffee Coffea plant
Coffee consumption was related to decreased
prevalence of NMSC in two studies [17, 18].
No association between coffee consumption and
NMSC in one study [19].
No [17–19]
Tea Camellia sinensis
Inconsistent results in human studies. Regular tea
consumption was associated with reduced risk of SCC
and BCC incidence in one study [20], but no
reduction in SCC risk in another study [21].
Case reported efficacy for basal cell nevus syndrome
with green tea body wrap [22].
No [20–22]
Escharotic
botanical
agents
Black salve
(containing bloodroot,
galangal, sheep sorrel, and red
clover)
Bloodroot
(Sanguinaria canadensis)
Cases reported no improvement of BCC and extensive
skin necrosis with black salve application [23, 24].
Case reported metastasis of BCC with bloodroot [25].
No [23–25]
Paclitaxel Taxus brevifolia
In vitro study demonstrated topical paclitaxel
increased antiproliferative activity in a squamous cell
carcinoma model [26].
Demonstrated clinical response to recurrent BCC
cases [27].
No [26, 27]
Beta-carotene Various plants with rich hues No efficacy for NMSCs. No [28, 29]
Table 2: Summary of the effects of botanical agents studied in mice that have also been studied in humans.
Botanical agent Source Efficacy References
Hypericin Hypericum perforatum
The combination of hypericin and
photodynamic therapy had poor efficacy in
one mouse model [30].
[30]
Tea Camellia sinensis Animal studies demonstrate catechins haveantitumor effects in mice [31–34]. [31–34]
3.3. Coffee. Coffee derives from seeds of the Coffea plant.
Inconsistent results have been found for the association
between coffee and various cancers. A prospective study by
Jacobsen et al. in Norway of 13,664 men and 2,891 women
demonstrated a strong inverse association between coffee
drinking and NMSC [17]. Furthermore, a hospital-based
case control study by Corona et al. of 166 case patients
with histopathologically confirmed BCC and 158 control
patients found that there was no statistically significant
association between coffee consumption and BCC risk in a
Mediterranean population from central-southern Italy [19].
More recently, Abel et al. performed a cross-sectional
analysis of 93,676 Caucasian women in the Women’s Health
Initiative Observational Study to determine the relationship
between consumption of coffee on a daily basis with the
prevalence of NMSCs [18]. They found that women who
drank caffeinated coffee daily had a 10.8% lower occurrence of
NMSCs compared to women who did not drink coffee. After
adjusting for lifestyle and demographic variables, they found
that daily consumption of six or more cups of coffee had a
30% reduction in occurrence of NMSC [18]. Consumption
of decaffeinated coffee was not related to a significant change
in rate of NMSCs. The authors concluded that, in Caucasian
women, daily consumption of caffeinated coffee had a dose-
related association with decreased occurrence of NMSC.
3.4. Tea. Dried and unfermented Camellia sinensis leaves are
often used primarily for green and black tea and have
anti-inflammatory and anticarcinogenic properties. Previous
mouse models demonstrated that green tea catechins or
polyphenols, such as the major catechin (-)-epigallocatechin
and (-)-epigallocatechin-3-gallate (EGCG), may protect
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against UVB radiation-induced NMSC [50, 51]. EGCG is
believed to act as a scavenger of reactive oxygen species [52]
andmay augment the native antioxidant defensemechanisms
of the cell.
A study by Lu et al. demonstrated that when hairless
mice were irradiated with UVB light twice weekly for a
total of 20 weeks followed three weeks later by treatment
with topical caffeine or EGCG once daily for five days over
18 weeks, the number of cutaneous tumors decreased [31].
Application of caffeine reduced the number of malignant and
nonmalignant skin tumors by 72% and 44%, respectively, and
EGCG reduced the number of malignant and nonmalignant
tumors by 66% and 55% [31]. Further immunohistochemical
analysis demonstrated that EGCG and caffeine augmented
apoptosis in nonmalignant cutaneous tumors and in squa-
mous cell carcinomas, but did not affect the epidermis lacking
tumor cells. Wang et al. demonstrated that oral consumption
of leaf extracts from caffeinated black and green tea and
decaffeinated black and green tea, similar to the composition
of tea beverages for humans, decreased the risk of UVB-
induced skin tumor formation in hairless mice [32].
Expanding on the animal studies, the use of green tea
and its ingredients have been studied in humans. Asgari
et al. performed a case-control study of 415 cases from
the Kaiser Permanente Northern California database with
pathology-verified SCC in 2004 to determine the association
between tea consumption, containing C. sinensis, and SCC
risk [21]. Controls were matched based on age, gender, and
race and had no previous history of skin cancer. Asgari
et al. demonstrated no reduction in SCC risk with regular
consumption of tea, defined as consumption at least once
per week (OR = 1.11, 95% confidence interval (CI): 0.81–1.54)
[21].There was no association between SCC risk and the dose
or amount of tea consumed, duration or years of use, nor
the “cup-years” measurement, which accounts for dose and
duration simultaneously.
Rees et al. performed a case control study to determine
the relationship between regular tea consumption, defined
as one cup daily for one month, and the incidence of BCCs
and SCCs [20]. The type of tea consumed, such as black or
green tea, was not specified. Among the subjects, they had
770 people with BCC, 696 with SCC, and 715 sex- and age-
matched controls. They found that regular tea consumption
significantly lowered the risk of SCC (odds ratio, OR = 0.70,
95% confidence interval, CI = 0.53–0.92) [20].This reduction
was most noticeable in long-term tea drinkers and people
who drank two cups daily. Similarly, the study demonstrated
that tea consumption had an inverse relationship with the
development of BCC risk (OR = 0.79; 95% CI = 0.63–0.98)
[20]. However, this relationship was weaker with regards
to SCCs. The authors report that there may be a possible
effect of citrus peel used in tea associated with the decreased
SCC risk, however, they did not investigate this possible
association further. Furthermore, it is unclear the reason
for the differences in risk for BCCs and SCCs with tea
consumption.
In addition to oral consumption of tea, topical tea
application was reported in a 47-year-old female with basal
cell nevus syndrome. She used green tea body wraps once
per month for a year without any new BCCs developing in
that time. The ingredients in the gel wrap included green tea
primarily, as well as other plant extracts—ginger oil, algae,
calendula oil, and mustard oil [22].
3.5. Escharotic Agents. Black salve, a combination of botani-
cal agents, and bloodroot are two escharotic botanical agents
that have been described in isolated case reports for their use
in NMSCs. One case reported a 63-year-old male with a BCC
confirmed by histopathology and located below the right eye
[23].ThoughMohsmicrographic surgerywas recommended,
the patient chose to self-treat the BCC with black salve
ointment containing 300mg of bloodroot, galangal, sheep
sorrel, and red clover. However, he had no improvement
and, ultimately, underwent Mohs surgery. Ten years prior to
developing the BCC, he had a suspected melanoma on the
left naris, which he treated with black salve. Although the
lesion resolved, he had extensive tissue damage at the site of
application andwas leftwith an absent left naris [23]. Another
case report of an 87-year-old male with a biopsy-proven BCC
treated with black salve resulted in complete loss of the nasal
ala at the site of application [24]. With regards to bloodroot,
a 52-year-old man with recurrent BCC on the nose treated
with Sanguinaria canadensis, bloodroot, instead of surgery
resulted inmetastasis of the BCC to the distal bones anddeath
of the patient [25].
3.6. Paclitaxel. Paclitaxel is a plant alkaloid derived from the
bark of the Pacific yew tree Taxus brevifolia. It is known
as a chemotherapy agent. Paclitaxel binds tubulin of micro-
tubules and stabilizes the microtubule structure to block its
breakdown and, therefore, inhibits cell division leading to
apoptosis of the cancer cells [53, 54]. It is more commonly
used to treat Kaposis sarcoma, nonsmall cell lung cancer,
breast cancer, and ovarian cancer. However, there are many
side effects with the intravenous administration of paclitaxel.
Therefore, Paolino et al. studied the use of a topical colloid
formulation for paclitaxel, paclitaxel-loaded ethosomes, a
vehicle devised to decrease systemic side effects and improve
patient compliance [26]. In their in vitro study, Paolino et al.
demonstrated that the paclitaxel-loaded ethosomes increased
the antiproliferative activity of paclitaxel in an SCC model.
Paclitaxel has also been reported in two cases for the treat-
ment of BCC. A 60-year-old male with a sclerosing BCC on
the right eyelid refractory to local therapy, surgery, radiation,
and six cycles of cisplatin and capecitabine was subsequently
treated with paclitaxel 175 milligrams per square meter
(mg/m2) intravenously every 21 days for a total of 15 cycles.
Complete responsewith elimination of the BCCwas achieved
after 12 cycles. The patient tolerated the treatment well and
remained in complete remission documented clinically 13
months from his first cycle of treatment [27]. In another
case report, a 74-year-old male with right scapular and nodal
axillary relapse of BCCafter surgical excisionwas treatedwith
cisplatin 75mg/m2 intravenously and paclitaxel 75mg/m2
intravenously every 21 days. Partial response was noted after
five cycles including elimination of pleural effusion, nodal
and skin involvement. However, the patient died following
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Table 3: Summary of the effects of botanical agents investigated only in preclinical studies.
Botanical agent Source Efficacy References
Curcumin Curcuma longa Linn Curcumin inhibits skin tumor carcinogenesis in mice. [35–41]
Genistein Soy, Greek sage, Greek oregano,and gingko biloba extract Genistein inhibits skin tumor carcinogenesis in mice. [42, 43]
Proanthocyanidin Grape seed
Grape seed proanthocyanidins demonstrated
anticarcinogenic effects against ultraviolet B-induced
skin tumors in mice.
[44, 45]
Lycopene Various plants with red pigment Lycopene prevents photodamage in mice and humans,suggesting potential for possible prevention of NMSC. [46, 47]
neurotoxicity and complications of deep venous thrombosis
and lung thromboembolism induced by chemotherapy [27].
3.7. Beta-Carotene. Beta carotene is a pigment found in a
variety of plants, including carrots and richly hued vegetables.
Many studies have demonstrated that a high consumption
of vegetables and fruits with a high concentration of beta
carotene has an inverse association with the risk of cancer
[55–59]. Greenberg et al. randomly assigned 1,805 patients
with a recent diagnosis of NMSC either 50mg of beta
carotene or placebo daily [28]. They followed the patients
with annual skin examinations up to five years. At the five year
endpoint, they found that therewas no difference between the
experimental and placebo groups in the rate of occurrence of
the first new NMSC (relative rate, RR = 1.05; 95% CI = 0.91–
1.22) [28]. In the U.S. Physicians’ Health Study, a randomized,
double-blind, placebo-controlled clinical trial, Frieling et al.
randomized 22,071 male participants to take beta-carotene
50mg every other day or placebo for 12 years [29]. They
found that beta carotene supplementation did not affect the
incidence of the first NMSC (RR = 0.98, 95% CI = 0.92–1.05),
including BCCs (RR = 0.99, 95% CI = 0.92–1.06) and SCCs
(RR = 0.97, 95% CI = 0.84–1.13) [29].
4. Botanical Agents Studied Only in
Preclinical Studies (Table 3)
4.1. Curcumin. Curcumin is a spice that originates from the
root of the Curcuma longa Linn plant and is the major
contributor to the yellow pigment in turmeric and curry.
It has been shown to have an anticarcinogenic effect; its
proposed mechanisms of action are that it either induces
apoptosis by augmenting the level of p53 [60] or it acti-
vates caspase-8, induced by the Fas receptor [61]. Topical
curcumin was found to have inhibitory activity against skin
tumor promotion in mice through mouse models [35–38,
58]. Furthermore, these studies demonstrated skin tumor
chemoprevention through inhibition of arachidonic acid
induced inflammation in vivo [37], inhibition of epidermal
cyclooxygenase and lipoxygenase activity in vitro [37, 39],
and suppression of oxidative stress through inhibition of
leukocyte infiltration into inflammatory regions [38]. Lim-
trakul et al. found that Swiss albino mice given a diet
containing 1% curcumin had significantly suppressed the
number of dimethylbenz[𝛼]anthracene (DMBA) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced skin tumors
per mouse (𝑃 < 0.05) and the tumor volume (𝑃 < 0.01)
as compared to mice on the standard diet [40]. Skin tumor
formation was initiated by 7,12-dimethylbenz[a]anthracene
(DMBA) and promoted with 12-O-tetradecanoylphorbol-13-
acetate (TPA). Furthermore, in a mouse skin cancer model,
Sonavane et al. found that curcumin at 15mg applied topically
had a similar effect as oral curcumin at 15mg for inhibiting
tumor growth [41]. However, no reports have been published
to assess the use of curcumin in human clinical trials.
4.2. Genistein. Genistein is a flavonoid found in soy, Greek
sage, Greek oregano, and ginkgo biloba extract and is
specifically a major isoflavone in soybeans. Studies have
shown that genistein have antioxidant and anticarcino-
genic activity in the skin [42, 62] as well as protection
against photodamage in mice [63]. Studies in mice have
demonstrated that genistein inhibits skin carcinogenesis.Wei
et al. demonstrated that genistein inhibited DMBA-initiated
and TPA-promoted skin carcinogenesis by treating SENCAR
(sensitive to carcinogenesis) mice with 10 micromoles of
topical genistein for one week [43]. A later study by Wei
et al. found that topical genistein also reduced ultraviolet
B-induced skin tumor multiplicity and incidence in hairless
mice [42]. Although there are no reported studies assessing
the effect of genistein on human skin cancer development,
genistein was found to inhibit UVB-induced photodamage in
a small study of six men [42]. Genistein was topically applied
to the six participants one hour prior to and five minutes
after they were UVB irradiated. The study demonstrated
that genistein applied to human skin inhibited UVB-induced
erythema. More specifically, topical application of genistein
prior to UVB irradiation inhibited erythema and cutaneous
discomfort while application after UVB irradiation improved
discomfort but had a weaker effect on erythema.
4.3. Grape Seed. Grape seeds contain proanthocyanidins, a
group of polyphenols that have been found to possess anti-
inflammatory and antioxidant properties [64, 65]. Although
not extensively studied nor investigated in clinical trials, the
proanthocyanidins have demonstrated possible anticarcino-
genic effects to ultraviolet-induced cutaneous tumors inmice.
Zhao et al. extracted proanthocyanidins in grape seeds after
grape seeds were air-dried and made into a powder. They
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demonstrated that proanthocyanidins in grape seeds had a
strong inhibitory effect for UVB-induced skin tumor devel-
opment in SENCARmice [44].Mittal et al. found that dietary
feeding of proanthocyanidins from grape seeds prevented
photocarcinogenesis in hairless mice as compared to mice on
the control diet [45]. Mice that consumed proanthocyanidins
had reduced tumor size (29%–94%), tumor incidence (20%–
95%), and tumor multiplicity (46%–95%) for UVB-induced
stages of photocarcinogenesis [45]. Furthermore, they found
that through in vivo and in vitro systems, photoprotection
was a result of antioxidant mechanisms.
4.4. Lycopene. Lycopene is a carotenoid that provides the
red pigmentation found in tomatoes, guava, watermelon,
pink grapefruit, papaya, rosehips, and other vegetables and
fruits. Though it is a phytochemical that lacks provitamin A
activity, lycopene has been studied for its anticarcinogenic
and antioxidant activity for breast [66], prostate [67], lung
[68], and colon cancer [69]. Fazekas et al. demonstrated
that topical lycopene application inhibitedUVB-induced skin
damage in mice [46]. Although a randomized controlled
trial by Rizwan et al. found that tomato paste containing a
high concentration of lycopene reduced ultraviolet-induced
skin erythema and markers of ultraviolet-induced DNA
damage (matrixmetalloproteinase-1 andmitochondrialDNA
3895 bp) [47], there are no reports assessing lycopene effects
on skin cancer in humans.
4.5. Silymarin. Silymarin is a flavonoid derived from Silybum
marianum, a milk thistle plant. It is known to have antioxi-
dant and anti-inflammatory properties [70, 71]. The primary
component in silymarin is silybin, which has demonstrated
to have anticarcinogenic properties for the cervix, breast,
and prostate [72]. Due to its antioxidant activity, silymarin
has been studied in mouse models for its effects on tumori-
genesis. Katiyar et al. found that silymarin inhibited UVB-
induced NMSC in hairless mice with topical silymarin in
three different protocols to assess the effects of silymarin at
various tumor stages [73]. Subsequently, Lahiri-Chatterjee
et al. demonstrated that application of silymarin to SENCAR
mice, in doses of 3, 6, and 12mg reduced tumor incidence
(by 25%, 40%, and 75%, 𝑃 < 0.001), tumor multiplicity (76%,
84%, 97%, 𝑃 < 0.001), and tumor volume (76%, 94%, 96%,
𝑃 < 0.001) [74]. Silymarin has not yet been investigated in
human clinical trials.
5. Utility against Nonmelanoma Skin Cancer
Ingenol mebutate, hypericin, coffee, tea, black salve, blood-
root, paclitaxel, and beta-carotene have been studied for
their effects on NMSC in humans or have been reported
to be used in humans with BCCs and SCCs. Clinical trials
assessing the effectiveness of ingenol mebutate on BCCs and
SCCs and case reports with patients using paclitaxel for
BCCs suggest efficacy of these agents for treating NMSCs
in humans. Despite favorable results, more human studies
are needed to assess the chemopreventive and therapeutic
effects of these botanical agents. In particular, prospective
trials with efficacy as the primary outcome are still needed.
Furthermore, black salve and bloodroot were reported to
be more harmful than therapeutic. Participants taking beta
carotene showed no difference in skin cancer rate compared
to the control groups. Although clinical response has been
reported using hypericin with photodynamic therapy, coffee,
and tea in humans with NMSCs, there is no consensus as to
the effectiveness of these agents based on the results of the
studies. Finally, it is important to note that in short studies,
such as the study of ingenol mebutate by Siller et al. that
lasted only 12 weeks [14], histopathological examination for
clearance ismore appropriate rather than clinical observation
for clearance. In this regard, this study was a phase IIa
study with the intent to assess side effects, and the primary
intent was not to assess treatment efficacy. Topical ingenol
appears to be well-tolerated overall. Although it is tempting
to speculate that application on sequential days may be better
than spacing the applications by a week, a study specifically
designed to assess efficacy is awaited before any conclusions
regarding the treatment of superficial BCCs can be drawn.
Although histopathological evaluation of clearance is
the gold standard, future studies should consider additional
incorporation of confocal microscopy. Confocal microscopy
may have a role in noninvasively assessing superficial BCC
recurrence [75–77]. Further studies will be needed to assess
its efficacy in delineating recurrences in studies with botani-
cal agents that may have a significant component of inflam-
mation in addition to wound healing.
Five botanical agents appear to have potential for
anticarcinogenesis based on preclinical studies. Curcumin,
genistein, grape seed proanthocyanidin, and silymarin have
demonstrated reduction in UV-induced skin cancers inmice,
and lycopene has been shown to prevent photodamage in
mice and humans. However, one botanical agent that has
been studied for its effects on NMSCs, beta carotene, does
not appear to be effective against skin cancer. Curcumin,
genistein, grape seed, lycopene, and silymarin have not yet
been studied in humans for the treatment or prevention of
NMSC.
6. Role of Lipophilicity and Hydrophilicity
An important characteristic that is highly important for
topical delivery of botanical agents is their hydrophilicity and
lipophilicity. Phytochemical subgroups that tend to be more
hydrophilic, such as polyphenol, may not penetrate the stra-
tum corneumwell.Thismay explain why topical polyphenols
do not seem to be as efficacious as oral/systemic delivery.
On the other hand, topical delivery of more lipophilic
phytochemicals, such as ingenol or silymarin, will be able
to penetrate the stratum corneum more effectively. One
option in conducting studies with agents that have a lower
partition coefficient will be to facilitate their transit through
the stratum corneum through penetration enhancers such
as liposomes, iontophoresis, sonophoresis, or microneedle
technology. Our suggestion for future evaluation of topical
botanicals is that investigators take the octanol-water par-
tition coefficient or the mode of extraction of the extract
into account in designing future studies. For example, a
nonaqueous extract or a phytochemical with a high partition
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coefficient may not require a penetration enhancer; on the
other hand, it would be prudent to consider the use of
penetration enhancers when studying aqueous extracts or
phytochemicals with low partition coefficients.
7. Conclusions
In vitro and in vivo models have been developed with the
hypothesis that natural products rich in complex chemicals
that have been shown to induce apoptosis in animal models
of chemoprevention may therefore possess the ability to
arrest the cell cycle at different stages and, therefore, control
the proliferation of cancer cells. Botanical agents have been
studied, and some have been reported to have favorable
effects against NMSC.
In this review, we have included a variety of botanical
agents that have been studied or reported for the treatment
of NMSCs. A limitation of this review is that we did not
include botanical agents that were reported in a single case
or a single preclinical study. However, we have provided an
up-to-date and concise review of botanical agents used in
NMSC that is currently found in the literature. Although
the limited preclinical data and clinical data available in the
literature demonstrate favorable effects of some botanical
agents on NMSC, for now, surgical therapy is the preferred
mode of treatment for high-risk NMSCs. Botanical agents
may have a preventive role in the development of cutaneous
malignancies and a potentially therapeutic role for carefully
chosen localized NMSCs of an appropriate subtype. The
topical use of some botanical extracts and phytochemicals
in the treatment of NMSC is promising. However, more
studies, both preclinical and clinical, are needed to make
more definitive conclusions regarding safety and efficacy.
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